Generic Lumigan Availability

Lumigan is a brand name of bimatoprost ophthalmic, approved by the FDA in the following formulation(s):

LUMIGAN (bimatoprost - solution/drops;ophthalmic)

  • Manufacturer: ALLERGAN
    Approval date: March 16, 2001
    Strength(s): 0.03% [RLD]
  • Manufacturer: ALLERGAN
    Approval date: August 31, 2010
    Strength(s): 0.01% [RLD]

Has a generic version of Lumigan been approved?

No. There is currently no therapeutically equivalent version of Lumigan available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lumigan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
    Patent 5,688,819
    Issued: November 18, 1997
    Inventor(s): Woodward; David F. & Andrews; Steven W. & Burk; Robert M. & Garst; Michael E.
    Assignee(s): Allergan
    The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.
    Patent expiration dates:
    • August 19, 2014
      ✓ 
      Patent use: TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
    • August 19, 2014
      ✓ 
      Patent use: LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
  • Enhanced bimatoprost ophthalmic solution
    Patent 7,851,504
    Issued: December 14, 2010
    Inventor(s): Chang; Chin-Ming & Chang; James N. & Schiffman; Rhett M. & Jordan; R. Scott & Chang-Lin; Joan-En
    Assignee(s): Allergan, Inc.
    A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Patent expiration dates:
    • June 13, 2027
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Enhanced bimatoprost ophthalmic solution
    Patent 8,278,353
    Issued: October 2, 2012
    Inventor(s): Chang; Chin-Ming & Chang; James N. & Schiffman; Rhett M. & Jordan; R. Scott & Chang-Lin; Joan-En
    Assignee(s): Allergan, Inc.
    A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein.
    Patent expiration dates:
    • March 16, 2025
      ✓ 
      Drug product
  • Enhanced bimatoprost ophthalmic solution
    Patent 8,299,118
    Issued: October 30, 2012
    Inventor(s): Chang; Chin-Ming & Chang; James N. & Schiffman; Rhett M. & Jordan; R. Scott & Chang-Lin; Joan-En
    Assignee(s): Allergan, Inc.
    A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Patent expiration dates:
    • March 16, 2025
      ✓ 
      Patent use: A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION
  • Enhanced bimatoprost ophthalmic solution
    Patent 8,309,605
    Issued: November 13, 2012
    Inventor(s): Chang; Chin-Ming & Chang; James N. & Schiffman; Rhett M. & Jordan; R. Scott & Chang-Lin; Joan-En
    Assignee(s): Allergan, Inc.
    A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Patent expiration dates:
    • March 16, 2025
      ✓ 
      Patent use: METHOD OF TREATING GLAUCOMA IN A PATIENT
    • March 16, 2025
      ✓ 
      Patent use: A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
  • Enhanced bimatoprost ophthalmic solution
    Patent 8,338,479
    Issued: December 25, 2012
    Inventor(s): Chang; Chin-Ming & Chang; James N. & Schiffman; Rhett M. & Jordan; R. Scott & Chang-Lin; Joan-En
    Assignee(s): Allergan, Inc.
    A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Patent expiration dates:
    • March 16, 2025
      ✓ 
      Patent use: A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION
      ✓ 
      Drug product
  • Enhanced bimatoprost ophthalmic solution
    Patent 8,524,777
    Issued: September 3, 2013
    Assignee(s): Allergan Inc.
    A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Patent expiration dates:
    • March 16, 2025
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION
  • Enhanced bimatoprost ophthalmic solution
    Patent 8,586,630
    Issued: November 19, 2013
    Assignee(s): Allergan, Inc.
    A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Patent expiration dates:
    • March 16, 2025
      ✓ 
      Patent use: A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • August 31, 2013 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web5)